RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
1-Year Return
18.15%
This Quarter Return
+0.23%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.56B
AUM Growth
-$299M
(-3.8%)
Cap. Flow
+$595M
Cap. Flow
% of AUM
7.87%
Top 10 Holdings %
Top 10 Hldgs %
53.85%
Holding
87
New
11
Increased
24
Reduced
6
Closed
9
Top Buys
| 1 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$130M |
| 2 |
Recursion Pharmaceuticals
RXRX
|
$115M |
| 3 |
Arcellx
ACLX
|
$88.5M |
| 4 |
Avidity Biosciences
RNA
|
$86.5M |
| 5 |
Biogen
BIIB
|
$56M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$91.9M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$54.6M |
| 3 |
Cytek Biosciences
CTKB
|
$45.7M |
| 4 |
VXRT
Vaxart
VXRT
|
$20M |
| 5 |
EyePoint Pharmaceuticals
EYPT
|
$19.4M |
Sector Composition
| 1 | Healthcare | 99.86% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Axsome Therapeutics
AXSM
$6.21B
| $80.5M | 1.06% |
1,000,000
| – | – |
|
27
Apogee Therapeutics
APGE
$2.21B
| $77.2M | 1.02% |
1,961,863
-16,038
| -0.8% | -$631K |
|
28
GH Research
GHRS
$872M
| $77M | 1.02% |
6,601,689
+349,975
| +6% | +$4.08M |
|
29
Structure Therapeutics
GPCR
$1.14B
| $74.5M | 0.99% |
1,896,772
+386,410
| +26% | +$15.2M |
|
|
LENZ
30
LENZ Therapeutics
LENZ
$1.14B
| $72.3M | 0.96% |
4,178,823
| – | – |
|
31
Fulcrum Therapeutics
FULC
$372M
| $72M | 0.95% |
11,609,704
| – | – |
|
32
Nkarta
NKTX
$151M
| $63.9M | 0.84% |
10,805,129
| – | – |
|
33
Dianthus Therapeutics
DNTH
$794M
| $60.4M | 0.8% |
2,333,000
| – | – |
|
34
Mineralys Therapeutics
MLYS
$2.2B
| $56.8M | 0.75% |
4,850,984
| – | – |
|
|
ITOS
35
DELISTED
iTeos Therapeutics
ITOS
| $52.2M | 0.69% |
3,517,259
-900,000
| -20% | -$13.4M |
|
36
UroGen Pharma
URGN
$870M
| $51.7M | 0.68% |
3,083,430
| – | – |
|
37
Praxis Precision Medicines
PRAX
$970M
| $51.1M | 0.68% |
1,235,599
+407,219
| +49% | +$16.8M |
|
38
Enliven Therapeutics
ELVN
$1.19B
| $49.6M | 0.66% |
2,122,465
| – | – |
|
39
Acrivon Therapeutics
ACRV
$40.9M
| $48.4M | 0.64% |
8,340,508
+3,530,000
| +73% | +$20.5M |
|
40
Astria Therapeutics
ATXS
$395M
| $45.9M | 0.61% |
5,043,756
+630,606
| +14% | +$5.74M |
|
|
BCYC
41
Bicycle Therapeutics
BCYC
$483M
| $45.6M | 0.6% |
2,253,000
+1,453,000
| +182% | +$29.4M |
|
42
CG Oncology
CGON
$2.36B
| $44.1M | 0.58% |
1,397,433
| – | – |
|
43
Larimar Therapeutics
LRMR
$331M
| $43.8M | 0.58% |
6,045,351
| – | – |
|
44
Acumen Pharmaceuticals
ABOS
$84.2M
| $36.1M | 0.48% |
14,932,063
| – | – |
|
45
Tourmaline Bio
TRML
$645M
| $32.7M | 0.43% |
+2,538,925
| New | +$32.7M |
|
|
THRD
46
DELISTED
Third Harmonic Bio
THRD
| $26.4M | 0.35% |
2,033,056
| – | – |
|
47
Solid Biosciences
SLDB
$433M
| $24.6M | 0.32% |
4,330,446
| – | – |
|
48
Taysha Gene Therapies
TSHA
$889M
| $24.4M | 0.32% |
10,872,503
| – | – |
|
49
Tenaya Therapeutics
TNYA
$202M
| $23.6M | 0.31% |
7,622,347
+1,867,297
| +32% | +$5.79M |
|
50
Vor Biopharma
VOR
$244M
| $22.7M | 0.3% |
22,748,880
| – | – |
|